The combined elevation of MPO and Histones at a cutoff > 2.09 for MPO and > 1.45 for Histones can be regarded as promising biomarkers for timely initiating NETs inhibitors in APLS, which is supposed to significantly lower thrombotic events, improve associated anemia and coagulopathy with better control of disease activity. This evidence concerns the gene MPO and anemia (phenotype).